Redcare Pharmacy Q3 sales jump 25% as German Rx revenue soars 82%

Redcare Pharmacy (ETR:RDC) reported robust Q3 results, with total group revenue increasing 25% to €719 million, primarily driven by an 82% year-over-year surge in German prescription sales to €126 million and 42.3% growth in total Rx sales. The online pharmacy operator reaffirmed its full-year guidance, citing strong momentum, profitable growth, and a year-to-date EBITDA margin already within its 2-2.5% full-year range. This performance, alongside an expanding active customer base and expected continued growth in German Rx, reinforces management's confidence in its operational trajectory.

Analysis

Asia stocks: Nikkei soars to record high as Takaichi win fuels stimulus bets Investing.com -- Redcare Pharmacy N.V. (ETR:RDC) on Monday said third-quarter prescription sales in Germany surged 82% year over year to €126 million, lifting total group revenue 25% to €719 million. The online pharmacy operator reaffirmed its full-year guidance following broad growth across both prescription and non-prescription categories. The Netherlands-based company said total prescription, or Rx, sales rose 42.3% to €272 million from €191 million a year earlier, while non-prescription, or non-Rx, sales increased 16.7% to €448 million. Year to date, total revenue climbed 27% to €2.15 billion, up €450 million from the prior-year period. Both of Redcare’s reporting segments recorded double-digit growth. Revenue in the DACH region, covering Germany, Austria and Switzerland, rose 25.2% to €587 million from €469 million. Within that segment, non-Rx sales grew 13.4% to €315 million, and Rx sales advanced 42.3% to €272 million. The company reported that year-to-date revenue in the DACH region reached €1.74 billion, up 26.7%. Sales in the International segment, which includes Belgium, Italy, France and the Netherlands, rose 25.4% to €132 million from €105 million. Year-to-date revenue for the segment totaled €402 million, an increase of 25.9%. At the end of the third quarter, Redcare said it had 13.7 million active customers, an increase of 200,000 since the previous quarter. The company’s net promoter score, a measure of customer satisfaction, improved to well over 70, up from 64 recorded in the first half of 2025. “We are delivering strong Q3 momentum, especially in German Rx where we grew double-digits quarter over quarter, and confirm full-year guidance,” Chief executive officer Olaf Heinrich said in a statement. “Growth remains profitable and cash generative, with a solid Q3 EBITDA, lifting our year-to-date margin already to our full-year guidance range of 2 to 2.5%,” Heinrich added. Redcare said it expects to reach at least €500 million in prescription sales for the full year, supported by the continued expansion of its German Rx business and seasonal increases in order volumes during the final quarter. The company reaffirmed all elements of its full-year guidance. Management said financial operations remain stable during the current transition period and that continuity is ensured until the appointment of a new chief financial officer. Should you invest $2,000 in RDC right now? First, check if it's included in one of this month's AI-powered stock strategies for ProPicks AI. Investing.com created these strategies to identify the most exciting trading opportunities currently in the market. The stocks that made the cut could produce monster returns in the coming years, like ViaSat and Sapiens, both up over 60%+ each in Q2 of 2025 alone. Is RDC one of them? Redcare Pharmacy N.V. (ETR:RDC) delivered a robust third-quarter performance, with total group revenue increasing 25% year-over-year to €719 million. This growth was primarily fueled by an exceptional 82% surge in German prescription (Rx) sales, which reached €126 million. The company demonstrated broad-based strength, as total Rx sales grew 42.3% to €272 million, while non-prescription sales posted a solid 16.7% increase. Geographically, both the core DACH region and the International segment recorded balanced, double-digit growth of 25.2% and 25.4%, respectively. Operational metrics support this financial momentum, with the active customer base expanding by 200,000 to 13.7 million and customer satisfaction, measured by the Net Promoter Score, improving significantly to over 70. Critically, management reaffirmed its full-year guidance, noting that the year-to-date EBITDA margin already falls within the annual target range of 2% to 2.5%, underscoring a commitment to profitable and cash-generative growth. The company anticipates full-year prescription sales to reach at least €500 million, signaling strong confidence heading into the final quarter.

Key Decisions for Investors

• Investors should recognize the reaffirmed full-year guidance and strong Q3 results as a significant validation of Redcare's growth trajectory, particularly its ability to capitalize on the German e-prescription market.
• The primary metric to monitor is the continued momentum in the German Rx segment, as its 82% year-over-year growth rate is the core driver of the current investment thesis.
• Given the CEO's emphasis on profitable growth, investors should assess whether the company can sustain its EBITDA margin within the 2-2.5% target range as it continues to scale its operations in Q4 and beyond.
• While management has assured operational stability during the CFO transition, the timely appointment of a permanent successor should be monitored as a key governance milestone.